Capital International Inc. CA Raises Stock Holdings in Amgen Inc. $AMGN

Capital International Inc. CA boosted its position in Amgen Inc. (NASDAQ:AMGN) by 10.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 425,513 shares of the medical research company’s stock after buying an additional 38,729 shares during the quarter. Amgen makes up about 1.1% of Capital International Inc. CA’s holdings, making the stock its 19th largest position. Capital International Inc. CA’s holdings in Amgen were worth $139,275,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of AMGN. Dogwood Wealth Management LLC boosted its holdings in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the period. Anfield Capital Management LLC boosted its holdings in shares of Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares during the period. Board of the Pension Protection Fund bought a new position in shares of Amgen in the fourth quarter worth $26,000. Manning & Napier Advisors LLC boosted its holdings in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares during the period. Finally, Olistico Wealth LLC bought a new position in shares of Amgen in the fourth quarter worth $33,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.

Amgen Stock Up 1.2%

Shares of NASDAQ:AMGN opened at $349.58 on Friday. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29. The company has a market cap of $188.67 billion, a PE ratio of 24.33, a P/E/G ratio of 3.51 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The stock’s 50-day moving average is $341.35 and its 200 day moving average is $345.47.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the business earned $4.90 EPS. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts anticipate that Amgen Inc. will post 22.38 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on AMGN shares. Cantor Fitzgerald reissued a “neutral” rating and set a $350.00 price objective on shares of Amgen in a research note on Wednesday, April 8th. Morgan Stanley set a $332.00 price objective on Amgen in a research note on Friday, May 1st. UBS Group lifted their price objective on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Canaccord Genuity Group started coverage on Amgen in a research note on Monday, April 20th. They set a “hold” rating and a $366.00 price objective for the company. Finally, Leerink Partners reissued a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research note on Thursday, March 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $353.81.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.